{"filing":{"accession_number":"0001213900-26-074017","cik":"0001631487","ticker":"CLGN","company_name":"CollPlant Biotechnologies Ltd","form":"6-K","filing_date":"2026-07-01","report_date":null,"primary_document":"ea0296519-6k_collplant.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1631487/000121390026074017/ea0296519-6k_collplant.htm"},"events":[{"id":15338,"run_id":13688,"accession_number":"0001213900-26-074017","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"CollPlant announced a private placement of 7,647,061 unregistered ordinary shares plus warrants (series A and B) at $0.34 per share, raising approximately $2.6 million. This is a classic dilutive equity issuance under Section 4(a)(2) and Regulation D, with unregistered securities sold to private investors. The company explicitly states the securities are unregistered and will require a registration statement for resale, and the warrants provide additional dilution potential (22.9 million additional shares if both series are exercised). For a small-cap biotech company with a history of significant losses and capital needs, this represents a material dilutive financing event.","company_name":"CollPlant Biotechnologies Ltd","ticker":"CLGN","filing_date":"2026-07-01","form":"6-K","submitted_at":null,"items":[{"id":13062,"accession_number":"0001213900-26-074017","item_number":"EX-99.1","item_title":"ea029651901ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"CollPlant announced a private placement of 7,647,061 unregistered ordinary shares plus warrants (series A and B) at $0.34 per share, raising approximately $2.6 million. This is a classic dilutive equity issuance under Section 4(a)(2) and Regulation D, with unregistered securities sold to private investors. The company explicitly states the securities are unregistered and will require a registration statement for resale, and the warrants provide additional dilution potential (22.9 million additional shares if both series are exercised). For a small-cap biotech company with a history of significant losses and capital needs, this represents a material dilutive financing event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-01T12:38:37.988635+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13062,"accession_number":"0001213900-26-074017","item_number":"EX-99.1","item_title":"ea029651901ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"CollPlant announced a private placement of 7,647,061 unregistered ordinary shares plus warrants (series A and B) at $0.34 per share, raising approximately $2.6 million. This is a classic dilutive equity issuance under Section 4(a)(2) and Regulation D, with unregistered securities sold to private investors. The company explicitly states the securities are unregistered and will require a registration statement for resale, and the warrants provide additional dilution potential (22.9 million additional shares if both series are exercised). For a small-cap biotech company with a history of significant losses and capital needs, this represents a material dilutive financing event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-01T12:38:37.988635+00:00","company_name":"CollPlant Biotechnologies Ltd","ticker":"CLGN","filing_date":"2026-07-01"}]}